What is the recommended management for peripheral artery disease, including lifestyle modifications, pharmacologic therapy, and indications for revascularization?

Peripheral Artery Disease Treatment

All patients with symptomatic PAD should receive aspirin (75-325 mg daily) or clopidogrel (75 mg daily) as antiplatelet therapy, combined with high-intensity statin therapy, supervised exercise training for at least 30-45 minutes three times weekly for 12 weeks minimum, and cilostazol (100 mg twice daily) for lifestyle-limiting claudication in the absence of heart failure. 1

Cardiovascular Risk Reduction (Mandatory for All PAD Patients)

Antiplatelet Therapy

• Aspirin (75-325 mg daily) is first-line antiplatelet therapy to reduce MI, stroke, and vascular death in symptomatic PAD 1
• Clopidogrel (75 mg daily) is an equally effective alternative to aspirin 1
• Dual pathway inhibition with rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily should be considered for high ischemic risk patients without high bleeding risk, particularly after revascularization 1
• Dual antiplatelet therapy (aspirin plus clopidogrel) may be considered post-revascularization to reduce limb-related events, though cardiovascular benefit is uncertain 1
• Warfarin added to antiplatelet therapy is contraindicated due to increased bleeding risk without cardiovascular benefit 1

Lipid Management

• Statin therapy is mandatory for all PAD patients regardless of baseline cholesterol levels 1
• Target LDL cholesterol <3.1 mmol/L (approximately <120 mg/dL) 2

Blood Pressure Control

• Antihypertensive therapy reduces MI, stroke, heart failure, and cardiovascular death 1
• ACE inhibitors or ARBs are preferred agents as they reduce cardiovascular ischemic events in PAD 1

Smoking Cessation

• Advise cessation at every visit with behavioral counseling 1
• Pharmacotherapy with varenicline, bupropion, and/or nicotine replacement should be offered 1

Symptom Management for Intermittent Claudication

Exercise Therapy (First-Line Treatment)

• Supervised exercise training is the initial treatment before considering revascularization 1
• Minimum program specifications: 30-45 minutes per session, at least 3 times weekly, for minimum 12 weeks 1
• High-intensity walking (77-95% maximal heart rate or 14-17 on Borg scale) improves walking performance 1
• Structured home-based programs with behavioral change techniques are acceptable when supervised programs are unavailable 1
• Unsupervised, unstructured walking recommendations alone are ineffective 1

Pharmacologic Therapy for Claudication

Cilostazol (First-Line)

• Cilostazol 100 mg twice daily is indicated to improve symptoms and walking distance 1
• Should be considered in all patients with lifestyle-limiting claudication 1
• Contraindicated in heart failure 1

Pentoxifylline (Second-Line)

• Pentoxifylline 400 mg three times daily may be considered as second-line alternative to cilostazol 1
• Clinical effectiveness is marginal and not well established 1

Ineffective or Harmful Therapies

• L-arginine, propionyl-L-carnitine, and ginkgo biloba have unestablished effectiveness 1
• Chelation therapy (EDTA) is contraindicated due to potential harm 1

Indications for Revascularization

When to Consider Revascularization

Revascularization is indicated when:

• Vocational or lifestyle-limiting disability from claudication persists after inadequate response to 3 months of exercise and pharmacological therapy 1
• Very favorable risk-benefit ratio exists (e.g., focal aortoiliac disease) 1
• Critical limb-threatening ischemia (CLTI) with compromised limb viability 3
• Acute limb ischemia 3

Revascularization is NOT indicated for:

• Asymptomatic PAD patients 1
• Prophylaxis to prevent progression to CLTI 1

Endovascular vs. Surgical Approach

Endovascular (Preferred for Specific Anatomies)

• TASC type A iliac and femoropopliteal lesions: endovascular is preferred revascularization 1
• Common and external iliac artery stenoses/occlusions: stenting is effective as primary therapy 1
• Iliac arteries: provisional stent placement for suboptimal balloon dilation results 1
• Femoral-popliteal lesions: drug-eluting treatment should be considered first-choice 1
• Primary stenting NOT recommended in femoral, popliteal, or tibial arteries 1

Surgical (Preferred When)

• Autologous vein (e.g., great saphenous vein) is available for femoral-popliteal lesions in low surgical risk patients 1, 4
• Autogenous grafts are superior to prosthetic grafts for popliteal or distal bypasses 4

Post-Revascularization Management

• Supervised exercise training is recommended as adjuvant therapy after endovascular revascularization 1
• Consider dual pathway inhibition (rivaroxaban 2.5 mg twice daily plus aspirin) to reduce cardiovascular and limb events 1

Critical Limb-Threatening Ischemia (CLTI)

• Early recognition and referral to vascular team is mandatory for limb salvage 1
• Offloading mechanical stress is required for ulcer healing 1
• WIfI score enables structured amputation risk assessment 2
• Revascularization is indicated to preserve limb viability 3

Common Pitfalls to Avoid

• Do not perform revascularization without first attempting 3 months of supervised exercise and medical therapy for claudication 1
• Do not use primary stenting in femoral-popliteal-tibial arteries except as salvage for failed balloon angioplasty 1
• Do not add warfarin to antiplatelet therapy without another indication due to bleeding risk 1
• Do not recommend unstructured "just walk more" programs as they are ineffective 1
• Do not withhold cilostazol in appropriate candidates—it has Level A evidence for symptom improvement 1